SEC Form 4 · accession 0001209191-16-113717
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marc Belsky
Officer — Senior Vice President and CFO
Period of report
Apr 6, 2016
Accepted (ET)
Apr 8, 2016 · 2:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 6, 2016 | M | 351 | $4.56 | A | 81,278 | D | |
| Common Stock | Apr 6, 2016 | M | 11,382 | $6.89 | A | 92,660 | D | |
| Common Stock | Apr 6, 2016 | M | 8,943 | $8.49 | A | 101,603 | D | |
| Common Stock | Apr 6, 2016 | M | 138 | $5.54 | A | 101,741 | D | |
| Common StockF2 | Apr 6, 2016 | S | 20,814 | $45.04 | D | 80,927 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $4.56 | Apr 6, 2016 | M | 351 | D | — | Oct 20, 2019 | Common Stock | 351 | 0 | D |
| Employee Stock Option (right to buy)F3 | $6.89 | Apr 6, 2016 | M | 11,382 | D | — | Jul 28, 2020 | Common Stock | 11,382 | 0 | D |
| Employee Stock Option (right to buy)F3 | $8.49 | Apr 6, 2016 | M | 8,943 | D | — | Jul 13, 2021 | Common Stock | 8,943 | 0 | D |
| Employee Stock Option (right to buy)F4 | $5.54 | Apr 6, 2016 | M | 138 | D | — | Jul 15, 2022 | Common Stock | 138 | 7,992 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on November 30, 2015.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from 45.00 to $45.16, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.
- F3This option is fully vested and immediately exercisable.
- F4This option began vesting on July 12, 2012 at a rate of 1/48th per month.